GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Renal Associates Holdings Inc (NYSE:ARA) » Definitions » ROE %

American Renal Associates Holdings (American Renal Associates Holdings) ROE % : 0.00% (As of Sep. 2020)


View and export this data going back to 2016. Start your Free Trial

What is American Renal Associates Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. American Renal Associates Holdings's annualized net income for the quarter that ended in Sep. 2020 was $-10.8 Mil. American Renal Associates Holdings's average Total Stockholders Equity over the quarter that ended in Sep. 2020 was $-77.0 Mil. Therefore, American Renal Associates Holdings's annualized ROE % for the quarter that ended in Sep. 2020 was N/A%.

The historical rank and industry rank for American Renal Associates Holdings's ROE % or its related term are showing as below:

ARA's ROE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -6.13
* Ranked among companies with meaningful ROE % only.

American Renal Associates Holdings ROE % Historical Data

The historical data trend for American Renal Associates Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Renal Associates Holdings ROE % Chart

American Renal Associates Holdings Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROE %
Get a 7-Day Free Trial Negative Equity Negative Equity - - -

American Renal Associates Holdings Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity Negative Equity - Negative Equity -

Competitive Comparison of American Renal Associates Holdings's ROE %

For the Diagnostics & Research subindustry, American Renal Associates Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Renal Associates Holdings's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Renal Associates Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where American Renal Associates Holdings's ROE % falls into.



American Renal Associates Holdings ROE % Calculation

American Renal Associates Holdings's annualized ROE % for the fiscal year that ended in Dec. 2019 is calculated as

ROE %=Net Income (A: Dec. 2019 )/( (Total Stockholders Equity (A: Dec. 2018 )+Total Stockholders Equity (A: Dec. 2019 ))/ count )
=-13.79/( (-58.464+-78.919)/ 2 )
=-13.79/-68.6915
=N/A %

American Renal Associates Holdings's annualized ROE % for the quarter that ended in Sep. 2020 is calculated as

ROE %=Net Income (Q: Sep. 2020 )/( (Total Stockholders Equity (Q: Jun. 2020 )+Total Stockholders Equity (Q: Sep. 2020 ))/ count )
=-10.764/( (-74.977+-78.975)/ 2 )
=-10.764/-76.976
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2020) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


American Renal Associates Holdings  (NYSE:ARA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2020 )
=Net Income/Total Stockholders Equity
=-10.764/-76.976
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.764 / 838.756)*(838.756 / 1179.95)*(1179.95 / -76.976)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1.28 %*0.7108*N/A
=ROA %*Equity Multiplier
=-0.91 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2020 )
=Net Income/Total Stockholders Equity
=-10.764/-76.976
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-10.764 / 50.604) * (50.604 / 88.776) * (88.776 / 838.756) * (838.756 / 1179.95) * (1179.95 / -76.976)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -0.2127 * 0.57 * 10.58 % * 0.7108 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2020) net income data. The Revenue data used here is four times the quarterly (Sep. 2020) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


American Renal Associates Holdings ROE % Related Terms

Thank you for viewing the detailed overview of American Renal Associates Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


American Renal Associates Holdings (American Renal Associates Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 6550, Beverly, MA, USA, 01915
American Renal Associates Holdings Inc is a joint venture-focused dialysis services provider in the United States. The company through its subsidiary is engaged in providing kidney dialysis services for patients suffering from chronic kidney failure, also known as end-stage renal disease. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.
Executives
Don E Williamson officer: EVP, Chief Operating Officer 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Victoria Labriola officer: VP and General Counsel AMERICAN RENAL HOLDINGS, INC. 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Joseph A Carlucci director, officer: Chief Executive Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Syed T Kamal director, officer: President C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Jeremy Gelber director C/O CENTERBRIDGE PARTNERS, L.P., 375 PARK AVE, 12TH FLOOR, NEW YORK NY 10152
Christopher J Hocevar director 1601 CHESTNUT STREET SHAREHOLDER SERVICES TL05Y PHILADELPHIA PA 19192
Robert H Fish director C/O SKILLED HEALTHCARE 27442 PORTOLA PARKWAY, SUITE 200 FOOTHILL RANCH CA 92610
Michael Boxer director 9151 BOULEVARD 26 NORTH RICHLAND HILLS TX 76180
John M Jureller director FRONTIER COMMUNICATIONS, 401 MERRITT 7, NORWALK CT 06851
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Jason Boucher officer: Former VP & CFO 500 CUMMINGS CENTER SUITE 6550 BEVERLY MA 01915
Mark Herbers officer: Interim CFO and Interim CAO 500 CUMMINGS CENTER, SUITE 6550, BEVERLY MA 01915
Michael Ray Costa officer: VP and General Counsel C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Patrick T Ryan director 401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880
Jonathan L Wilcox officer: VP & Chief Financial Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915

American Renal Associates Holdings (American Renal Associates Holdings) Headlines

From GuruFocus